@article{article_558418, title={The prevalence of metabolic syndrome and its components in benign and malignant nodular thyroid diseases.}, journal={Pamukkale Medical Journal}, volume={12}, pages={423–431}, year={2019}, DOI={10.31362/patd.558418}, author={Can, Sevinc and Anıl, Cuneyd and Nar, Asli and Gursoy, Alptekin}, keywords={Metabolik sendrom,insülin direnci,tiroid,nodül,benign,malign}, abstract={<p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;">Purpose: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;"> Metabolic syndrome (MetS) is
a condition harboring a group of metabolic abnormalities <sup> </sup>where
insulin resistance (IR) plays a major role. The aim of our study is to evaluate
MetS and its components in patients with benign and malignant nodular thyroid
disease (NTD). </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;">Materials and methods: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;"> A
total of 800 patients (430 euthyroid benign nodular and 370 euthyroid malignant
NTD) were analyzed for MetS and its components. Serum insulin levels and IR estimated
by homeostasis model assessment (HOMA-IR), as well as other MetS parameters
were evaluated. </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;">Results: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;"> Metabolic syndrome was
detected in 59.8% of 800 patients. There was no significant difference between
benign and malignant NTD groups related to the prevalence of the MetS (61.4% in
benign nodular group, 57.8% in malignant nodular group, <i>p </i>>0.05). The most common MetS component was abdominal obesity
(65%), followed by low HDL-C level (64.8%), and high blood glucose level
(30.8%). When patients with benign and malignant NTD were evaluated separately,
the occurrence of the MetS components were found in similar frequency in the
benign group compared to the overall average. In the malignant group, it was
determined that low HDL-C level was the most common and high blood pressure was
the least common component. There was no significant difference between benign
and malignant NTD groups in terms of insulin levels and HOMA-IR. </span> </p> <p> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;">Conclusions: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:Arial, sans-serif;"> The results suggest
that patients with NTD have significantly increased MetS prevalence compared to
patients without NTD. However, there was no significant difference between
benign and malignant NTD in this respect. </span> </p>}, number={3}, publisher={Pamukkale University}